GV20 Therapeutics
Business Services · 51-200 Employees
View Company Info for Free
Overview
Website
www.gv20tx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
1
1
1
1
1
About GV20 Therapeutics
GV20 specializes in high throughput functional genomics and AI methodologies to identify new drug targets in cancer immunology. The company focuses on discovering and developing effective antibody drugs for cancer treatment. GV20 has established a robust portfolio of immuno-oncology antibody drug candidates. Their intended clients include pharmaceutical companies and research institutions involved in cancer therapeutics.Explore more
GV20 Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is GV20 Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if GV20 Therapeutics is spiking on competitors!
Check if GV20 Therapeutics has recently received funding, and reach out quickly before it becomes old news!
GV20 Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at GV20 Therapeutics
Click to see if GV20 Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when GV20 Therapeutics launches new products
Earning: See what the market has to say on GV20 Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once GV20 Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at GV20 Therapeutics
Find more new buyers
Compare Similar Companies to GV20 Therapeutics
Compare insights from companies similar to GV20 Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$29.6M
51-200
Private
$277.8M
2020
Michael SecoraChief Financial Officer & Chief Corporate Development Officer
Company Profile Activity
Activity Insights
GV20 Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
GV20 Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about GV20 Therapeutics.
GV20 Therapeutics Tech Stack
A closer look at the technologies used by GV20 Therapeutics
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Event
Events, Engineering, Sales, Bioengineering, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Operations
Event
Product Marketing, Events, Business Intelligence, Engineering, Analytics & Insights, Research & Development, Sales, Search, Software, Bioengineering, Laboratory Operations, Clinical Operations, Field Marketing, Operations
Person-Based
Event
Events, Engineering, Research & Development, Training, Machine Learning, Learning & Development, Search, Laboratory Operations, Medical Education & Training, Medical Research, Chemical Engineering, Artificial Intelligence, Clinical Operations, Healthcare Technology, HR Operations, Operations
GV20 Therapeutics News & Media
GV20 Therapeutics Announces Achievement of Milestone under Antibody-Drug Conjugate Collaboration with Mitsubishi Tanabe Pharma Corporation
NEWTON, Mass., Nov. 25, 2025 /PRNewswire/ -- GV20 Therapeutics (GV20), a clinical-stage AI-powered biotherapeutics company, announced that it has received a milestone payment under its collaboration agreement with Mitsubishi Tanabe Pharma Corporation (MTPC). GV20 and MTPC entered into...GV20 Therapeutics to Present Updated Phase 1 Monotherapy Data on GV20-0251 at the ASCO Annual Meeting 2025
NEWTON, Mass., May 23, 2025 /PRNewswire/ -- GV20 Therapeutics (GV20), a clinical-stage AI-powered biotherapeutics company, today announced that Dr. Kristopher Wentzel from the Angeles Clinic and Research Institute will present updated clinical and translational data of GV20-0251...GV20 Therapeutics Announces Collaboration Agreement with Mitsubishi Tanabe Pharma Corporation to Develop Novel Antibody-Drug Conjugates
NEWTON, Mass., March 26, 2025 /PRNewswire/ -- GV20 Therapeutics (GV20), a clinical-stage AI-powered biotherapeutics company, has entered into a strategic research collaboration with Mitsubishi Tanabe Pharma Corporation (MTPC). Under this collaboration, MTPC will leverage GV20's...GV20 Therapeutics Presents Promising Phase 1 Monotherapy Data on Novel Checkpoint Inhibitor GV20-0251 at ESMO Congress 2024
BOSTON, Sept. 16, 2024 /PRNewswire/ -- GV20 Therapeutics, a clinical-stage AI-based next generation biotherapeutics company, today announced presentation of clinical results from its Phase 1/2 study of GV20-0251 at the European Society for Medical Oncology (ESMO) Congress 2024 in...
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding GV20 Therapeutics
Sign Up For FreeTo access detailed company insights
GV20 specializes in high throughput functional genomics and AI methodologies to identify new drug targets in cancer immunology. The company focuses on discovering and developing effective antibody drugs for cancer treatment. GV20 has established a robust portfolio of immuno-oncology antibody drug candidates. Their intended clients include pharmaceu... Read More
